BackNewAmsterdam Pharma Company NV Overview
NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company NV Target Price

See NewAmsterdam Pharma Company NV's analyst price targets ($51) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$25.4

Average Target Price

$51.33102.1% upside

3 analysts in the last 4 months

High: $58 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-20BMO Capital$58128.3% upsideOpen
2026-07-20JefferiesDennis Ding$4577.2% upsideOpen
2026-06-30RBC Capital$51100.8% upsideOpen
2026-02-19Guggenheim$4577.2% upsideOpen
2026-01-21RBC Capital$4785% upsideOpen
2026-01-06Leerink PartnersRoanna Ruiz$55116.5% upsideOpen
2025-12-02Goldman Sachs$3745.7% upsideOpen
2025-10-20H.C. WainwrightJoseph Pantginis$52104.7% upsideOpen
2025-08-25Wells Fargo$4577.2% upsideOpen
2025-03-03UBS$4161.4% upsideOpen
2024-12-30H.C. WainwrightEd Arce$4889% upsideOpen
2024-11-20Leerink PartnersRoanna Ruiz$4577.2% upsideOpen
2024-09-23Piper SandlerYasmeen Rahimi$3745.7% upsideOpen
2024-08-28NeedhamSerge Belanger$3641.7% upsideOpen

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV (NAMS) currently reports a target price of $51. Use the charts on this page to explore NewAmsterdam Pharma Company NV's target price history and peer comparisons.

Analysts' average 12-month price target for NewAmsterdam Pharma Company NV is $51, about 102.1% upside from the current share price of $25.4. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $51, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.